Clinical study on the effect of 99Tc MDP in the treatment of ischemic necrosis of lunate bone

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064951

Enrollment

Unknown

Registered

2022-10-24

Start date

2022-10-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic necrosis of lunate bone

Interventions

Group 1:99Tc-MDP

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for OOL; 2. Intense radioactive uptake of related osteoarthropathy on bone scan; 3. Follow-up time >= 12 months; 4. Ages 18-70.

Exclusion criteria

Exclusion criteria: 1. Suppurative osteomyelitis; 2. Gouty wrist arthritis; 3. Carpal tunnel syndrome (median nerve compression symptoms, such as numbness, pain and discomfort); 4. Reactive carpal arthritis; 5. Infectious wrist arthritis; 6. Severe liver and kidney diseases; 7. Tenosynovitis stricture; 8. Dorsal wrist ganglion cyst.

Design outcomes

Primary

Measure	Time frame
stages;Bone metabolism;	—

Secondary

Measure	Time frame
osteolytic lesions;Upper limb function;quality of life;pain;	—

Countries

China

Contacts

Public ContactChao Ma

Shanghai Tenth People's Hospital

ponymachao@163.com+86 21 66302075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026